| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 261.79% | Truist Securities | $32 → $25 | Maintains | Buy |
| 09/21/2023 | 305.21% | Cantor Fitzgerald | → $28 | Reiterates | Overweight → Overweight |
| 09/20/2023 | 203.91% | RBC Capital | $20 → $21 | Maintains | Outperform |
| 09/20/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
| 08/11/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
| 08/11/2023 | 189.44% | RBC Capital | $21 → $20 | Maintains | Outperform |
| 08/11/2023 | 363.1% | Truist Securities | $42 → $32 | Maintains | Buy |
| 08/11/2023 | 88.13% | Ladenburg Thalmann | $17 → $13 | Maintains | Buy |
| 08/11/2023 | 189.44% | Baird | $24 → $20 | Maintains | Outperform |
| 08/11/2023 | 102.6% | Oppenheimer | → $14 | Downgrades | Outperform → Perform |
| 06/23/2023 | 305.21% | Cantor Fitzgerald | $28 → $28 | Reiterates | Overweight → Overweight |
| 06/14/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
| 05/30/2023 | 160.49% | JMP Securities | → $18 | Reiterates | Market Outperform → Market Outperform |
| 05/12/2023 | 507.81% | Truist Securities | $50 → $42 | Maintains | Buy |
| 05/12/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
| 04/25/2023 | 218.38% | RBC Capital | → $22 | Reiterates | → Outperform |
| 04/25/2023 | 102.6% | Oppenheimer | $12 → $14 | Maintains | Outperform |
| 03/08/2023 | 305.21% | Cantor Fitzgerald | → $28 | Reiterates | → Overweight |
| 03/08/2023 | 218.38% | RBC Capital | $23 → $22 | Maintains | Outperform |
| 03/08/2023 | 160.49% | JMP Securities | $19 → $18 | Maintains | Market Outperform |
| 03/08/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | → Buy |
| 01/23/2023 | 232.85% | SVB Leerink | $27 → $23 | Maintains | Outperform |
| 01/20/2023 | 232.85% | RBC Capital | → $23 | Initiates Coverage On | → Outperform |
| 11/09/2022 | 247.32% | Baird | $32 → $24 | Maintains | Outperform |
| 03/22/2022 | 623.59% | Truist Securities | $35 → $50 | Maintains | Buy |
| 03/22/2022 | 218.38% | JMP Securities | $21 → $22 | Maintains | Market Outperform |
| 03/22/2022 | 290.74% | SVB Leerink | $30 → $27 | Maintains | Outperform |
| 12/20/2021 | 334.15% | SVB Leerink | $32 → $30 | Maintains | Outperform |
| 09/30/2020 | 406.51% | Truist Securities | → $35 | Initiates Coverage On | → Buy |
| 09/28/2020 | 406.51% | HC Wainwright & Co. | $9 → $35 | Maintains | Buy |
| 09/15/2020 | 15.77% | SVB Leerink | $6 → $8 | Maintains | Outperform |
| 07/01/2020 | 30.25% | HC Wainwright & Co. | $6 → $9 | Maintains | Buy |
| 07/01/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 05/05/2020 | -13.17% | Cantor Fitzgerald | $7 → $6 | Reiterates | → Overweight |
| 01/10/2020 | -13.17% | HC Wainwright & Co. | $5 → $6 | Reiterates | → Buy |
| 12/20/2019 | -13.17% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 10/18/2019 | 1.3% | Cantor Fitzgerald | → $7 | Assumes | → Overweight |
| 09/03/2019 | -27.64% | HC Wainwright & Co. | → $5 | Initiates Coverage On | → Buy |
| 03/05/2019 | 44.72% | Jefferies | → $10 | Initiates Coverage On | → Buy |
| 02/27/2019 | -27.64% | Mizuho | $13 → $5 | Downgrades | Buy → Neutral |
| 02/06/2019 | 44.72% | Leerink Swann | → $10 | Initiates Coverage On | → Outperform |
What is the target price for Marinus Pharma (MRNS)?
The latest price target for Marinus Pharma (NASDAQ: MRNS) was reported by Truist Securities on November 8, 2023. The analyst firm set a price target for $25.00 expecting MRNS to rise to within 12 months (a possible 261.79% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Marinus Pharma (MRNS)?
The latest analyst rating for Marinus Pharma (NASDAQ: MRNS) was provided by Truist Securities, and Marinus Pharma maintained their buy rating.
When is the next analyst rating going to be posted or updated for Marinus Pharma (MRNS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marinus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marinus Pharma was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating Marinus Pharma (MRNS) correct?
While ratings are subjective and will change, the latest Marinus Pharma (MRNS) rating was a maintained with a price target of $32.00 to $25.00. The current price Marinus Pharma (MRNS) is trading at is $6.91, which is out of the analyst's predicted range.